NCT03869268View on ClinicalTrials.gov

The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 24, 2019

Primary Completion Date

December 10, 2021

Study Completion Date

February 9, 2023

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Aspirin

Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.

DRUG

Ticagrelor

Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.

Trial Locations (1)

S5 7AU

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

All Listed Sponsors
lead

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER

NCT03869268 - The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin | Biotech Hunter | Biotech Hunter